Research Analysts Offer Predictions for EVAX FY2024 Earnings

Evaxion Biotech A/S (NASDAQ:EVAX) – Zacks Small Cap increased their FY2024 earnings estimates for shares of Evaxion Biotech A/S in a note issued to investors on Wednesday, January 15th. Zacks Small Cap analyst B. Sorensen now anticipates that the company will post earnings per share of ($0.16) for the year, up from their previous estimate of ($0.80). The consensus estimate for Evaxion Biotech A/S’s current full-year earnings is ($0.15) per share. Zacks Small Cap also issued estimates for Evaxion Biotech A/S’s Q4 2024 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.14) EPS and FY2025 earnings at ($0.74) EPS.

Evaxion Biotech A/S (NASDAQ:EVAX) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.40. The company had revenue of $3.02 million for the quarter, compared to the consensus estimate of $0.19 million.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $70.00 price objective on shares of Evaxion Biotech A/S in a research report on Friday, November 1st.

Evaxion Biotech A/S Price Performance

Shares of NASDAQ EVAX opened at $3.09 on Friday. The company has a fifty day moving average price of $6.17 and a 200 day moving average price of $11.74. Evaxion Biotech A/S has a 1-year low of $3.03 and a 1-year high of $68.05. The firm has a market cap of $18.14 million, a PE ratio of -10.66 and a beta of -0.23. The company has a current ratio of 1.00, a quick ratio of 2.80 and a debt-to-equity ratio of 7.99.

Institutional Trading of Evaxion Biotech A/S

An institutional investor recently raised its position in Evaxion Biotech A/S stock. Armistice Capital LLC raised its holdings in Evaxion Biotech A/S (NASDAQ:EVAX) by 6.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 392,000 shares of the company’s stock after buying an additional 25,000 shares during the period. Armistice Capital LLC owned 7.24% of Evaxion Biotech A/S worth $1,137,000 at the end of the most recent reporting period. 11.04% of the stock is currently owned by institutional investors and hedge funds.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.